Pay in 4 interest-free payments of $6.56 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Semaglutide leans entirely on GLP-1 appetite suppression, slowed gastric emptying, and glucose-dependent insulin release
A separate analysis of real-world data from the FDA Adverse Event Reporting System found similar patterns
Its stated directly in Wegovys own FDA label: WEGOVY delays gastric emptying
Vitamin D: 2,000-4,000 IU daily (adjust based on blood levels)
Instead of prescribing an antidepressant that might cause weight gain (making one problem better while worsening the other), we can consider a low-dose GLP-1 that might help both while the patient engages in therapy and lifestyle changes
Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist specifically licensed by the MHRA for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity (such as dysglycaemia, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease)
